Twist Bioscience Corporation (TWST) Stock Forecast
TWST analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.08 / 5 from 13 analysts
- Price target
- $163.67 average of analyst targets
- Upside to target
- +23.3% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.44
- 52-week range
- $25.45 – $205.00
TWST analyst ratings
13 analystsNumber of analysts at each rating.
TWST price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TWST earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.14 | −$0.31 | −$0.04 | −$0.50 | +72.4% | 3 |
| Current fiscal year (FY2026) | −$1.20 | −$2.14 | −$0.57 | −$2.12 | +43.5% | 5 |
| Next fiscal year (FY2027) | −$0.40 | −$1.12 | $0.10 | −$1.20 | +66.5% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TWST revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $126.4M | $124.0M | $128.1M | +21.9% | 8 |
| Current fiscal year (FY2026) | $456.3M | $455.9M | $457.1M | +21.2% | 12 |
| Next fiscal year (FY2027) | $548.6M | $532.4M | $559.9M | +20.2% | 11 |
TWST EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TWST revenue: reported and forecast
TWST EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.10 | −$0.16 | −$0.16 | −$0.16 | −$0.14 | +45.3% | 1 up · 0 down |
| Current fiscal year (FY2026) | −$1.19 | −$1.08 | −$0.96 | −$0.96 | −$1.20 | +0.8% | 2 up · 0 down |
| Next fiscal year (FY2027) | −$1.00 | −$0.78 | −$0.75 | −$0.75 | −$0.40 | −60.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TWST earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TWST beat in 9 of 12.
What analysts expect from TWST
13 analysts cover Twist Bioscience; their consensus rating is buy (4.08 on a 1–5 scale, where 5 is a strong buy). The average price target is $163.67, 23.3% above the latest close of $132.75. Analysts expect earnings of −$1.20 per share for FY2026, +43.5% from a year earlier. For FY2027 the average estimate is −$0.40 per share on revenue of $548.6 million. Twist Bioscience beat the EPS estimate in 9 of the last 12 quarters.
Related: TWST income statement, TWST key metrics, TWST chart. See the TWST stock overview for the latest quote and news.
TWST forecast FAQ
What is Twist Bioscience's price target?
The average analyst price target for Twist Bioscience is $163.67, 23.3% above the latest close of $132.75.
Is Twist Bioscience a buy, hold or sell?
Of 13 analysts covering Twist Bioscience, 7 rate it a strong buy, 2 a buy, 3 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Twist Bioscience's EPS forecast?
Analysts forecast −$1.20 per share for FY2026 (range −$2.14 to −$0.57); for FY2027 the estimate is −$0.40.
What is Twist Bioscience's revenue forecast?
The average revenue estimate for FY2026 is $456.3 million, growth of 21.2%; for FY2027 it is $548.6 million.
When does Twist Bioscience report earnings?
Twist Bioscience is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.44.
Does Twist Bioscience usually beat earnings estimates?
Twist Bioscience reported EPS at or above the analyst estimate in 9 of the last 12 quarters.